Nerandomilast, Boehringer Ingelheim’s investigational oral therapy, significantly slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) after a year of treatment, according to final data from two Phase 3 clinical trials. FIBRONEER-IPF (NCT05321069) enrolled 1,177 IPF patients, while FIBRONEER-ILD…
I couldn’t decide whether to open my column this week with “I hate this disease” or “This disease simply isn’t fair.” It’s been one of those weeks when both statements are true. I hate this disease, and this disease isn’t fair. The first few days after my idiopathic pulmonary fibrosis…
A Phase 2 clinical trial has begun recruiting that’s assessing the safety and efficacy of LTI-03, Rein Therapeutics’ inhaled therapy for idiopathic pulmonary fibrosis (IPF). RENEW (NCT06968845) is expected to enroll up to 120 people at about 50 sites in the U.S., U.K., Germany, Austria, and Poland.
After my mid-May clinic visit, I made my 130th medication change since my bilateral lung transplant in July 2021. Each week I fill my pill boxes with 17 medications. Another 17 have come out of rotation since my transplant. Following my diagnosis of idiopathic pulmonary fibrosis in January…
GRI Bio has reached an interim enrollment goal for its Phase 2a clinical trial testing GRI-0621 — a therapy targeting natural killer T-cells (NKT cells) to treat idiopathic pulmonary fibrosis (IPF) — and expects to report initial results later this quarter, per a company press release. With…
Leave no stone unturned. This is a basic tenet of any investigation, something I learned very early in my career as a special agent. It also seems to be a practice employed by my healthcare team, which now includes an additional doctor. Last week, I added endocrinologist Oksana Davydov…
A committee of the European Medicines Agency (EMA) is recommending orphan drug status — a designation that aims to speed therapy development in rare diseases — for tranilast, the active ingredient in NXP002, an inhaled formulation from Nuformix for treating idiopathic pulmonary fibrosis (IPF). A decision by the…
Disrupting the rhythm of day-to-day life with pulmonary fibrosis comes at a cost. When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, my medications changed dramatically. I went from taking only Zyrtec (cetirizine hydrochloride) for seasonal allergies to requiring multiple meds that…
A cancer immunotherapy known as ipilimumab was able to reduce scar formation and promote tissue regeneration in the lungs of a mouse model of idiopathic pulmonary fibrosis (IPF). Treatment boosted the immune system’s ability to clear senescent cells, or those that no longer divide or grow but accumulate in…
My adventure continues. At this point, regular readers might be thinking, “What now?” Some may even pause to make some popcorn before reading further. I was surprised when I was diagnosed with idiopathic pulmonary fibrosis in 2017, because I had led a relatively healthy life. Deciding to be positive on…
Get regular updates to your inbox.
